

Attachment B2

Summary of Public Comments and CDC Response

Federal Register Notice: A 60-day Notice was published in the *Federal Register* on February 17, 2012 (Vol. 77, No. 33, pp. 9660-9661).

Public Comment #1



April 16, 2012

Kimberly Lane
CDC Reports Clearance Officer
1600 Clifton Road, MS D-74
Atlanta, GA 20222

RE: CDC Cervical Cancer Study (CX3) (OMB No. 0920-0814)

Dear Ms. Lane


We thank you for the opportunity to provide comments on the CDC Cervical Cancer Study (CX3) referenced in the Federal Register notice on Friday, February 17, 2012. The American Cancer Society Cancer Action Network (ACS CAN), the nonpartisan advocacy affiliate of the American Cancer Society (ACS), supports continuing the CX3 pilot program to further explore the benefits and potential barriers of expanding screening in the National Breast and Cervical Cancer Screening Program (NBCCEDP) to include HPV testing.

Current reimbursable expenses under the NBCCEDP do not allow for HPV testing. As a result, women are not able to access HPV testing in combination with Pap testing, the preferred screening method for women over 30 according to ACS. Using both screening methods in combination allows women to extend the amount of time between screens. If including HPV testing along with PAP testing were to become a routine method of screening in the NBCCEDP program, women would be screened less often, ultimately allowing the program to provide more screenings to underserved women due to more available funds.

Since the release of this notice in the Federal Register, both ACS and the United States Preventative Services Task Force (USPSTF) individually updated their guidelines on cervical cancer screening. Both organizations now separately recommend that cervical cancer screening for women aged 30 years and older can be done using the HPV test combined with the Pap test every 5 years, providing that past results have been normal. Given the new guidelines, we request that the program updates to their research question to include the frequency guidelines for HPV testing in combination with Pap testing which are in accordance with the newly released ACS and USPSTF guidelines on cervical cancer screening.

Thank you for your time. For any additional questions, please contact Stephen Finan, Senior Director of Policy, (202) 661-5780 or by email, stephen.finan@cancer.org.

Sincerely,


Stephen Finan

Senior Director of Policy
American Cancer Society Cancer Action Network

CDC Response to Public Comment #1

CDC revised the instrument for focus groups with providers.